Karyopharm Therapeutics Inc. (KPTI) stock
KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
$0.04−0.01 (-20.00%)
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Karyopharm Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$65.35M. For fiscal 2025 it was -$75.37M. The highest annual figure on record is -$8.55M in fiscal 2011.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$75.37M | – |
| FY2024 | Dec 31, 2024 | -$127.49M | – |
| FY2023 | Dec 31, 2023 | -$92.72M | – |
| FY2022 | Dec 31, 2022 | -$149.55M | – |
| FY2021 | Dec 31, 2021 | -$107.12M | – |
| FY2020 | Dec 31, 2020 | -$160.23M | – |
| FY2019 | Dec 31, 2019 | -$190.82M | – |
| FY2018 | Dec 31, 2018 | -$159.12M | – |
| FY2017 | Dec 31, 2017 | -$73.72M | – |
| FY2016 | Dec 31, 2016 | -$84.39M | – |
| FY2015 | Dec 31, 2015 | -$94.03M | – |
| FY2014 | Dec 31, 2014 | -$51.45M | – |
| FY2013 | Dec 31, 2013 | -$30.29M | – |
| FY2012 | Dec 31, 2012 | -$15.51M | – |
| FY2011 | Dec 31, 2011 | -$8.55M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$38.98M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.81M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.45M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$43.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.59M | – |
| Q3 FY2023 | Sep 30, 2023 | -$29.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.84M | -205.4% |
| Q3 FY2022 | Sep 30, 2022 | -$28.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$35.14M | – |
| Q1 FY2022 | Mar 31, 2022 | -$59.20M | – |
| Q4 FY2021 | Dec 31, 2021 | $25.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.75M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.89M | – |
| Q4 FY2020 | Dec 31, 2020 | -$30.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$44.31M | – |
| Q2 FY2020 | Jun 30, 2020 | -$40.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$45.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$39.49M | – |
| Q3 FY2019 | Sep 30, 2019 | -$36.51M | – |
| Q2 FY2019 | Jun 30, 2019 | -$48.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$66.62M | – |
| Q4 FY2018 | Dec 31, 2018 | -$48.17M | – |
| Q3 FY2018 | Sep 30, 2018 | -$38.67M | – |
| Q2 FY2018 | Jun 30, 2018 | -$37.63M | – |
| Q1 FY2018 | Mar 31, 2018 | -$34.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.54M | – |
| Q3 FY2017 | Sep 30, 2017 | -$21.75M | – |
| Q2 FY2017 | Jun 30, 2017 | -$21.72M | – |
| Q1 FY2017 | Mar 31, 2017 | -$24.71M | – |
| Q4 FY2016 | Dec 31, 2016 | -$20.00M | – |
| Q3 FY2016 | Sep 30, 2016 | -$20.33M | – |
See a number that looks wrong?